Comments
Shares of Cadila Healthcare jumped nearly 3 per cent to Rs 360 as Zydus Cadila has received final approval from the US health regulator to market Clindamycin Phosphate Topical Solution, used to treat acne.
The company has received approval from the US Food and Drug Administration to market Clindamycin Phosphate Topical Solution USP (Cleocin T), 1 per cent.
Zydus Cadila has more than 204 approvals and has so far filed over 330 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
After opening the session at Rs 352 against the previous close of Rs 350.05, Cadila Healthcare shares touched intraday high of Rs 360 and a low of Rs 342 on the BSE. In terms of equity volume, 0.62 lakh shares exchanged hands in the morning trade.
Cadila Healthcare is the listed entity of drug major Zydus Cadila.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.